FDA Approval Summary: Pembrolizumab, Atezolizumab, and Cemiplimab-rwlc as single agents for first-line treatment of advanced/metastatic PD-L1 high NSCLC.
暂无分享，去创建一个
Jiang Liu | Martha Donoghue | R. Pazdur | Hong Zhao | J. Beaver | H. Singh | P. Mishra-Kalyani | Y. Gong | L. Pai-Scherf | Whitney S. Helms | Y. Bi | Joyce Cheng | M. Fiero | Jeanne Fourie Zirkelbach | M. Chuk | Hongshan Li | Yi Ren | I. Bulatao | Shyam Kalavar | Oladimeji Akinboro | S. Jafri | W. Fu | B. Osborn | Kun He | Yuan Xu | S. Sickafuse | L. Mathieu | Min Wang | Erin Larkins | Jonathan Herz | Rebecca Cohen | Luckson N Mathieu | E. Larkins